ALDX Stock Overview
A biotechnology company, develops and commercializes medicines for immune-mediated diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Aldeyra Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.49 |
| 52 Week High | US$6.61 |
| 52 Week Low | US$2.71 |
| Beta | 1.35 |
| 1 Month Change | 34.09% |
| 3 Month Change | 38.09% |
| 1 Year Change | 80.78% |
| 3 Year Change | 68.57% |
| 5 Year Change | 28.51% |
| Change since IPO | -9.86% |
Recent News & Updates
Recent updates
Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Feb 06
Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?
Jun 21Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?
Feb 16Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?
Nov 06Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Mar 26Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?
Nov 19Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment
Sep 14Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization
Aug 04Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?
Aug 03Aldeyra says trial for dry eye disease candidate reached key goals
Jul 12Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Apr 19Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts
Feb 17Shareholder Returns
| ALDX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9.4% | 0.4% | 1.5% |
| 1Y | 80.8% | -2.7% | 22.4% |
Return vs Industry: ALDX exceeded the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: ALDX exceeded the US Market which returned 22.4% over the past year.
Price Volatility
| ALDX volatility | |
|---|---|
| ALDX Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ALDX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ALDX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 9 | Todd Brady | www.aldeyra.com |
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss.
Aldeyra Therapeutics, Inc. Fundamentals Summary
| ALDX fundamental statistics | |
|---|---|
| Market cap | US$386.48m |
| Earnings (TTM) | -US$44.80m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.6x
P/E RatioIs ALDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALDX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$44.80m |
| Earnings | -US$44.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.75 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 18.0% |
How did ALDX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 10:37 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aldeyra Therapeutics, Inc. is covered by 21 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Ascendiant Capital Markets LLC |
| Esther Lannie Hong | Berenberg |
| Thomas Shrader | BTIG |